Document is current

Any future updates will be listed below

Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1038/s41401-022-00930-6

Published Online: 2022-06-15

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark